Ascentage Pharma Group International (NASDAQ:AAPG) Shares Gap Down – Here’s Why

Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) shares gapped down before the market opened on Friday . The stock had previously closed at $19.33, but opened at $18.52. Ascentage Pharma Group International shares last traded at $18.0660, with a volume of 165 shares.

Analyst Ratings Changes

Several brokerages have issued reports on AAPG. B. Riley Financial started coverage on shares of Ascentage Pharma Group International in a report on Wednesday, June 10th. They issued a “buy” rating and a $45.00 price target on the stock. BTIG Research restated a “buy” rating and set a $48.00 price objective on shares of Ascentage Pharma Group International in a research report on Monday, June 15th. Deutsche Bank Aktiengesellschaft began coverage on Ascentage Pharma Group International in a research report on Friday, April 24th. They set a “buy” rating and a $40.00 price objective for the company. China Intl Cap upgraded Ascentage Pharma Group International to a “strong-buy” rating in a report on Monday, April 6th. Finally, Raymond James Financial reiterated a “buy” rating on shares of Ascentage Pharma Group International in a report on Wednesday, June 10th. Two investment analysts have rated the stock with a Strong Buy rating and eight have given a Buy rating to the stock. According to MarketBeat.com, Ascentage Pharma Group International has a consensus rating of “Buy” and a consensus price target of $46.43.

Ascentage Pharma Group International Price Performance

The company has a quick ratio of 1.77, a current ratio of 1.79 and a debt-to-equity ratio of 0.57. The firm’s 50 day moving average is $18.59 and its two-hundred day moving average is $22.44.

Institutional Investors Weigh In On Ascentage Pharma Group International

A number of hedge funds and other institutional investors have recently modified their holdings of AAPG. Hsbc Holdings PLC purchased a new position in shares of Ascentage Pharma Group International during the second quarter valued at approximately $391,000. UBS Group AG boosted its position in Ascentage Pharma Group International by 149.4% during the third quarter. UBS Group AG now owns 18,345 shares of the company’s stock worth $716,000 after acquiring an additional 10,988 shares during the last quarter. Finally, Citadel Advisors LLC purchased a new stake in Ascentage Pharma Group International in the 3rd quarter worth approximately $383,000.

About Ascentage Pharma Group International

Ascentage Pharma Group International is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapeutics that modulate programmed cell death pathways, including the Bcl‐2 family and the MDM2–p53 axis. Its pipeline features orally bioavailable inhibitors such as APG-2575, a selective Bcl-2 inhibitor, and APG-115, a potent MDM2 antagonist, both aimed at reactivating apoptosis in cancer cells across hematologic malignancies and solid tumors.

Founded in 2008 by biotechnology entrepreneur Dr.